The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Links

 

Gene Review

INSL6  -  insulin-like 6

Homo sapiens

Synonyms: Insulin-like peptide 6, Insulin-like peptide INSL6, RIF1, Relaxin/insulin-like factor 1
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of INSL6

 

High impact information on INSL6

  • RESULTS: Hydralazine significantly reduced the 19F signal intensity in the murine tumors RIF-1 and KHT and in the HT29 human tumor, with little reduction in the SCCVII/Ha murine and HX118 human tumors [1].
  • Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors [6].
  • We have recently demonstrated evidence of IGF dependency in murine MGH-OGS and RIF-1 sarcomas, which express relatively high and intermediate levels of IGF-1 receptors [7].
  • This study shows that a Photofrin-induced photodynamic therapy-resistant variant (RIF-8A) of a radiation-induced fibrosarcoma-1 cell line (RIF-1) is cross-resistant to cis-diamminedichloroplatinum(II) (cisplatin) [8].
  • Immediately following a 1-h exposure to cisplatin (50 microM), RIF-1 cells contained 44.6 +/- 2.0 (SEM) pg platinum/micrograms DNA while RIF-8A cells contained 24.8 +/- 6.3 pg platinum/micrograms DNA [8].
 

Chemical compound and disease context of INSL6

 

Biological context of INSL6

  • A new member of the insulin gene family (INSL6) was identified from an Expressed Sequence Tag database through a search for proteins containing the insulin family B-chain cysteine motif [14].
  • The time course of bioenergetic changes in RIF-1 tumors determined by 31P-NMR spectroscopy was found to parallel the reduction and subsequent recovery of tumor blood flow [4].
  • The present experiments were conducted to determine the effects of cyclophosphamide (150 mg/kg) on the pathophysiology of RIF-1 solid tumors and to determine the temporal relationship between treatment mediated changes in tumor vascular physiology, cell proliferation, and chemoresponsiveness in vivo [15].
  • The resistance factors relative to RIF-1, calculated from full survival curves for cis-DDP, were 3.8 +/- 0.4 for Chinese hamster ovary cells and 8.8 +/- 0.7 for both A2780 and A1847 lines [16].
  • The kinetics of cis-DDP-DNA adduct formation and loss was investigated in RIF-1, A2780, and A1847 cells by the immunocytochemistry technique [16].
 

Anatomical context of INSL6

 

Associations of INSL6 with chemical compounds

  • In split-dose experiments, the time-dependent increases in the chemoresponsiveness of RIF-1 tumors, after cyclophosphamide, may be due not only to the increased proliferation of repopulating cells, but also to vascular responses attendant with cytoreduction [15].
  • In vitro, ketoconazole and IL-1 alpha induced only additive clonogenic cell kill in primary RIF-1 explant cultures [20].
  • Resistance does not appear to be the result of elevated glutathione levels since neither the resistant variant (RIF-8A) nor the parental line (RIF-1) varied in total glutathione levels [8].
  • The effect of elevated plasma corticosterone levels, induced by ketamine-acepromazine anesthesia, on IL-1 alpha responsiveness was also studied in the RIF-1 tumor model [20].
  • METHODS: A WAF1/iNOS/liposome complex was injected directly into RIF-1 and HT29 tumours in mice [21].
 

Other interactions of INSL6

  • Human INSL6 was 43% identical to human relaxin H2 in the B- and A-chain regions [14].
  • The exclusive expression pattern of RIF1 and related RLF in testis interstitial cells suggested potential physiological roles of these two distinct insulin/relaxin family ligands in testis function [22].
  • IL-1 alpha produced dose-dependent sensitization of clonogenic RIF-1 tumor cells to MMC in vivo [23].
  • Cell proliferation in RIF-1 tumors, assessed by [3H]thymidine labeling index and tumor growth fraction (primer-dependent DNA polymerase labeling assay) measurements, was inhibited for up to 3 days by cyclophosphamide [15].
 

Analytical, diagnostic and therapeutic context of INSL6

  • Northern blot analysis showed that RIF1 transcripts are approximately 1.2 kb in size and are expressed mainly in testis of mouse and human [22].
  • After RT-PCR, full-length cDNAs of RIF1 and RIF2 were obtained from mouse testis and ovary, respectively [22].
  • The IL-1-mediated hemorrhagic response was maximal 6-12 h after treatment and greater in Panc02 tumors than in RIF-1 tumors [24].
  • The volume-dependence of the HbO2 saturation status differed similarly among the tumor lines; HbO2 saturation status decreased with increasing tumor volume for the KHT, RIF-1, and MLS lines and was independent of tumor volume for the OWI line [25].
  • In s.c. RIF-1 tumors (C3H/HeJ mice) ketoconazole potentiated IL-1 alpha induced hemorrhagic necrosis (59Fe labeled RBC uptake) and prolonged intervals of low tumor perfusion (86Rb+ uptake) and attendant depletion of tumor high energy phosphate reserves as determined by in vivo 31P nuclear magnetic resonance spectroscopy [20].

References

  1. Use of fluorine-19 nuclear magnetic resonance spectroscopy and hydralazine for measuring dynamic changes in blood perfusion volume in tumors in mice. Thomas, C., Counsell, C., Wood, P., Adams, G.E. J. Natl. Cancer Inst. (1992) [Pubmed]
  2. Metastatic behavior of the RIF-1 murine fibrosarcoma: inhibited by hypophysectomy and partially restored by growth hormone replacement. Sekyi-Otu, A., Bell, R., Andrulis, I., Pollak, M. J. Natl. Cancer Inst. (1994) [Pubmed]
  3. Cryospectrophotometric determination of tumor intravascular oxyhemoglobin saturations: dependence on vascular geometry and tumor growth. Fenton, B.M., Rofstad, E.K., Degner, F.L., Sutherland, R.M. J. Natl. Cancer Inst. (1988) [Pubmed]
  4. 31P-nuclear magnetic resonance studies of the effect of recombinant human interleukin 1 alpha on the bioenergetics of RIF-1 tumors. Constantinidis, I., Braunschweiger, P.G., Wehrle, J.P., Kumar, N., Johnson, C.S., Furmanski, P., Glickson, J.D. Cancer Res. (1989) [Pubmed]
  5. Sensitivity of normal mouse marrow and RIF-1 tumour to hyperthermia combined with cyclophosphamide or BCNU: a lack of therapeutic gain. Honess, D.J., Bleehen, N.M. Br. J. Cancer (1982) [Pubmed]
  6. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors. Bellnier, D.A., Gollnick, S.O., Camacho, S.H., Greco, W.R., Cheney, R.T. Cancer Res. (2003) [Pubmed]
  7. Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary human sarcomas. Sekyi-Otu, A., Bell, R.S., Ohashi, C., Pollak, M., Andrulis, I.L. Cancer Res. (1995) [Pubmed]
  8. Cross-resistance to cisplatin in cells resistant to photofrin-mediated photodynamic therapy. Moorehead, R.A., Armstrong, S.G., Wilson, B.C., Singh, G. Cancer Res. (1994) [Pubmed]
  9. Interleukin 1 increases thymidine labeling index of normal tissues of mice but not the tumor. Zaghloul, M.S., Dorie, M.J., Kallman, R.F. Int. J. Radiat. Oncol. Biol. Phys. (1994) [Pubmed]
  10. 5-chlorodeoxycytidine, a radiosensitizer effective against RIF-1 and Lewis lung carcinoma, is also effective against a DMBA-induced mammary adenocarcinoma and the EMT-6 tumor in BALB/c mice. Greer, S., Santos, O., Gottlieb, C., Schwade, J., Marion, H.S. Int. J. Radiat. Oncol. Biol. Phys. (1992) [Pubmed]
  11. A double quantum coherence transfer proton NMR spectroscopy technique for monitoring steady-state tumor lactic acid levels in vivo. Freeman, D.M., Sotak, C.H., Muller, H.H., Young, S.W., Hurd, R.E. Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. (1990) [Pubmed]
  12. The response to carbogen breathing in experimental tumour models monitored by gradient-recalled echo magnetic resonance imaging. Robinson, S.P., Rodrigues, L.M., Ojugo, A.S., McSheehy, P.M., Howe, F.A., Griffiths, J.R. Br. J. Cancer (1997) [Pubmed]
  13. 31P-magnetic resonance spectroscopy and 2H-magnetic resonance imaging studies of a panel of early-generation transplanted murine tumour models. Robinson, S.P., van den Boogaart, A., Maxwell, R.J., Griffiths, J.R., Hamilton, E., Waterton, J.C. Br. J. Cancer (1998) [Pubmed]
  14. Identification of INSL6, a new member of the insulin family that is expressed in the testis of the human and rat. Lok, S., Johnston, D.S., Conklin, D., Lofton-Day, C.E., Adams, R.L., Jelmberg, A.C., Whitmore, T.E., Schrader, S., Griswold, M.D., Jaspers, S.R. Biol. Reprod. (2000) [Pubmed]
  15. Effect of cyclophosphamide on the pathophysiology of RIF-1 solid tumors. Braunschweiger, P.G. Cancer Res. (1988) [Pubmed]
  16. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Terheggen, P.M., Emondt, J.Y., Floot, B.G., Dijkman, R., Schrier, P.I., den Engelse, L., Begg, A.C. Cancer Res. (1990) [Pubmed]
  17. Radiation, pool size and incorporation studies in mice with 5-chloro-2'-deoxycytidine. Santos, O., Perez, L.M., Briggle, T.V., Boothman, D.A., Greer, S.B. Int. J. Radiat. Oncol. Biol. Phys. (1990) [Pubmed]
  18. Subcellular localization of Photofrin and aminolevulinic acid and photodynamic cross-resistance in vitro in radiation-induced fibrosarcoma cells sensitive or resistant to photofrin-mediated photodynamic therapy. Wilson, B.C., Olivo, M., Singh, G. Photochem. Photobiol. (1997) [Pubmed]
  19. Differential thermal sensitivity of tumour and normal tissue microvascular response during hyperthermia. Brown, S.L., Hunt, J.W., Hill, R.P. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group. (1992) [Pubmed]
  20. Potentiation of interleukin 1 alpha mediated antitumor effects by ketoconazole. Braunschweiger, P.G., Kumar, N., Constantinidis, I., Wehrle, J.P., Glickson, J.D., Johnson, C.S., Furmanski, P. Cancer Res. (1990) [Pubmed]
  21. Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment. Worthington, J., McCarthy, H.O., Barrett, E., Adams, C., Robson, T., Hirst, D.G. The journal of gene medicine. (2004) [Pubmed]
  22. Cloning of two novel mammalian paralogs of relaxin/insulin family proteins and their expression in testis and kidney. Hsu, S.Y. Mol. Endocrinol. (1999) [Pubmed]
  23. Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha. Braunschweiger, P.G., Jones, S.A., Johnson, C.S., Furmanski, P. Cancer Res. (1991) [Pubmed]
  24. Antitumor effects of recombinant human interleukin 1 alpha in RIF-1 and Panc02 solid tumors. Braunschweiger, P.G., Johnson, C.S., Kumar, N., Ord, V., Furmanski, P. Cancer Res. (1988) [Pubmed]
  25. 31P nuclear magnetic resonance spectroscopy studies of tumor energy metabolism and its relationship to intracapillary oxyhemoglobin saturation status and tumor hypoxia. Rofstad, E.K., DeMuth, P., Fenton, B.M., Sutherland, R.M. Cancer Res. (1988) [Pubmed]
 
WikiGenes - Universities